This was the stock's fourth consecutive day of gains.

Those who already own the stock may retain it for some time to see if VRTX's CF sales continue to rise and how the Casgevy launch progresses.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We've got lots ...

Shares have been on the move with the stock up 5.8% over the past month. The stock hit a new 52-week high of $58.22 in the previous session. Vertex has gained 6.2% since the start of the year compared ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

In a report released on January 21, Brian Abrahams from RBC Capital maintained a Hold rating on Vertex Pharmaceuticals (VRTX – Research ...

Cebranopadol, a dual-NMR agonist, reached the primary endpoint in a Phase III trial and matched placebo for safety, a ...

Vertex Energy has emerged as a privately held company after emerging from Chapter 11 bankruptcy. The company company filed for protections in 2024 after spending on equipment ...

The U.S. Bankruptcy Court for the Southern District of Texas allowed the company to exit bankruptcy as a privately-held company under the ownership of lenders. Those lenders include funds managed by ...

At J.P. Morgan, most biopharma executives expressed a neutral stance on the incoming administration, but just days later, ...

The AMD unified shader architecture that debuted in the Xbox 360 ushered in a new era for the graphics processing unit (GPU).

NEW YORK, NY / ACCESS Newswire / January 22, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Vertex ...